Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. CAPR
stocks logo

CAPR

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
480.00K
-78.78%
-0.549
+242.97%
--
--
-0.513
-3.15%
--
--
-0.530
-7.02%
Estimates Revision
The market is revising Downward the revenue expectations for Capricor Therapeutics, Inc. (CAPR) for FY2025, with the revenue forecasts being adjusted by -49.58% over the past three months. During the same period, the stock price has changed by 276.85%.
Revenue Estimates for FY2025
Revise Downward
down Image
-49.58%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-0.67%
In Past 3 Month
Stock Price
Go Up
up Image
+276.85%
In Past 3 Month
Wall Street analysts forecast CAPR stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for CAPR is 21.25 USD with a low forecast of 13.00 USD and a high forecast of 29.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Analyst Rating
Wall Street analysts forecast CAPR stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for CAPR is 21.25 USD with a low forecast of 13.00 USD and a high forecast of 29.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Buy
0 Hold
0 Sell
Strong Buy
Current: 25.400
sliders
Low
13.00
Averages
21.25
High
29.00
Current: 25.400
sliders
Low
13.00
Averages
21.25
High
29.00
H.C. Wainwright
H.C. Wainwright
Buy
maintain
$24 -> $60
2025-12-03
New
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$24 -> $60
2025-12-03
New
maintain
Buy
Reason
H.C. Wainwright raised the firm's price target on Capricor Therapeutics to $60 from $24 and keeps a Buy rating on the shares. Capricor rebounded from its July 2025 Complete Response Letter with a decisive clinical win, meeting its primary PUL v2.0 endpoint and the prospectively triggered Left Ventricular Ejection Fraction analysis, positioning its therapy to reach Duchenne muscular dystrophy patients, the analyst tells investors in a research note. With 78% of participants having underlying cardiomyopathy-addressing FDA concerns about sample size-and a conservative approval expectation of mid-2026, shares are likely to trade well into year-end, the firm says.
Alliance Global
NULL -> Buy
maintain
$16 -> $48
2025-12-03
New
Reason
Alliance Global
Price Target
$16 -> $48
2025-12-03
New
maintain
NULL -> Buy
Reason
Alliance Global raised the firm's price target on Capricor Therapeutics to $48 from $16 and keeps a Buy rating on the shares after the company read out topline data for their pivotal Phase 3 HOPE-3 trial of Deramiocel in 106 Duchenne Muscular Dystrophy patients. These data were unequivocally and wholly positive, in the firm's view. Alliance Global is removing its speculative tag.
Roth Capital
Boobalan Pachaiyappan
Buy
maintain
$12 -> $13
2025-11-11
Reason
Roth Capital
Boobalan Pachaiyappan
Price Target
$12 -> $13
2025-11-11
maintain
Buy
Reason
Roth Capital analyst Boobalan Pachaiyappan raised the firm's price target on Capricor Therapeutics to $13 from $12 and keeps a Buy rating on the shares. At the very least, the firm expects Phase 3 HOPE-3 results anticipated in Q4 tot show evidence of cardiac improvements during which case Capricor may pressure the agency to exercise regulatory flexibility to approve Deramiocel for the treatment of Duchenne muscular dystrophy cardiomyopathy, the analyst tells investors in a research note. The firm added that its models assumed Deramiocel approval in this sub-disease area.
Alliance Global Partners
Buy
maintain
$20 -> $16
2025-07-14
Reason
Alliance Global Partners
Price Target
$20 -> $16
2025-07-14
maintain
Buy
Reason
Alliance Global Partners lowered the firm's price target on Capricor Therapeutics to $16 from $20 and keeps a Buy rating on the shares after the company received a complete response letter from the FDA for deramiocel. The firm believes changes in the FDA administration most likely unfavorably impacted the company's application filing. However, Capricor's HOPE-3 trial results announcement in Q3 "may change FDA's outlook for the better," the analyst tells investors in a research note.
Roth Capital
Buy
downgrade
$31 -> $12
2025-07-14
Reason
Roth Capital
Price Target
$31 -> $12
2025-07-14
downgrade
Buy
Reason
Roth Capital lowered the firm's price target on Capricor Therapeutics to $12 from $31 and keeps a Buy rating on the shares. The FDA's Complete Response Letter - CRL - for Deramiocel well ahead of the PDUFA timeline of August 31 was a "surprise" as all eyes now turn to HOPE-3 top-line data expected in Q3, though the firm still expects positive HOPE-3 data and potential BLA approval in mid-2026, the analyst tells investors in a research note.
H.C. Wainwright
Joseph Pantginis
Buy
downgrade
$77 -> $24
2025-07-11
Reason
H.C. Wainwright
Joseph Pantginis
Price Target
$77 -> $24
2025-07-11
downgrade
Buy
Reason
H.C. Wainwright analyst Joseph Pantginis lowered the firm's price target on Capricor Therapeutics to $24 from $77 and keeps a Buy rating on the shares after the company received a complete response letter from the FDA for deramiocel, its cell therapy candidate for the treatment of cardiomyopathy in Duchenne muscular dystrophy patients. The firm does not see the CRL "as the end of the story." The FDA offered Capricor the opportunity to request a Type A meeting, and H.C. Wainwright's positive thesis on deramiocel being approved for DMD cardiomyopathy following resubmission remains unchanged, the analyst tells investors in a research note. The firm pushed out the approval year for deramiocel to 2026 from 2025.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Capricor Therapeutics Inc (CAPR.O) is -21.31, compared to its 5-year average forward P/E of -5.20. For a more detailed relative valuation and DCF analysis to assess Capricor Therapeutics Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-5.20
Current PE
-21.31
Overvalued PE
5.88
Undervalued PE
-16.29

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-5.03
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
17.00
Undervalued EV/EBITDA
-27.06

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
113.29
Current PS
0.00
Overvalued PS
338.83
Undervalued PS
-112.25
Intellectia AI SwingMax
Intellectia AI SwingMax

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Financial AI Agent
Financial AI Agent

CAPR News & Events

Events Timeline

(ET)
2025-12-04
17:00:00
Piper Sandler and Oppenheimer Act as Joint Book Running Managers for the Offering
select
2025-12-04
16:10:00
Capricor Therapeutics Announces Proposed Underwritten Public Offering of Common Stock
select
2025-12-03 (ET)
2025-12-03
16:20:00
Major US Indices Close Higher as Markets Price in Fed Rate Cut This Month
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.0
12-04NASDAQ.COM
PinnedPositive Outlook for Capricor as They Prepare to Address Complete Response Letter

  • Positive Trial Results: Capricor Therapeutics reported successful topline results from its Phase 3 HOPE-3 trial of Deramiocel, showing a 54% slowing of skeletal muscle disease progression in Duchenne Muscular Dystrophy (DMD) patients and a 91% slowing of decline in left ventricular ejection fraction.

  • Safety and Efficacy: Deramiocel demonstrated a favorable safety profile and achieved statistical significance in both primary and secondary endpoints, reinforcing its potential benefits for muscle and heart function in DMD patients.

  • Regulatory Plans: Capricor plans to submit the HOPE-3 data to the FDA in response to a Complete Response Letter issued earlier, aiming for regulatory approval of Deramiocel, which has already received Orphan Drug and RMAT designations.

  • Stock Performance: Following the trial results, Capricor's stock price surged significantly, closing at $29.96 after reaching an intraday high of $40.37, reflecting a 371% increase.

[object Object]
Preview
9.0
12-04Benzinga
PinnedCapricor Shares Surge as Shkreli Takes a Short Position: Insights from the Pharma Bro

  • Capricor's Stock Surge: Capricor Therapeutics' stock skyrocketed by 356% after announcing positive topline data from the Phase 3 HOPE-3 trial for its cell therapy candidate, deramiocel.

  • Martin Shkreli's Short Position: Former pharma executive Martin Shkreli, who had publicly bet against Capricor's success, faced significant losses as the stock surge resulted in a "short squeeze."

  • Controversy Over Data Presentation: Following the data release, Shkreli criticized Capricor for allegedly changing the primary endpoint of the study and suggested that the results were based on questionable analyses.

  • Regulatory Implications: Capricor's CEO stated that the HOPE-3 results provide strong evidence for the therapy's effectiveness in treating Duchenne muscular dystrophy and will be used to address a previous FDA Complete Response Letter.

[object Object]
Preview
9.0
12-03Benzinga
PinnedCapricor Therapeutics' Duchenne Treatment Demonstrates Promising Heart and Muscle Outcomes in Clinical Trial

  • Capricor Therapeutics Stock Surge: Capricor Therapeutics Inc. (NASDAQ: CAPR) experienced a significant stock rally following the release of positive topline results from its Phase 3 HOPE-3 trial for Deramiocel, a cell therapy for Duchenne muscular dystrophy (DMD).

  • Trial Results: The trial involved 106 participants, with results showing that nearly 54% of patients experienced slowed disease progression and about 91% showed improvement in heart function, marking a significant achievement in DMD treatment.

  • Expert Commentary: Investigators highlighted the trial's success in meeting its primary endpoint, emphasizing the potential of Deramiocel to significantly impact critical aspects of DMD, particularly heart function.

  • Regulatory Background: Earlier in July, Capricor received a Complete Response Letter from the FDA regarding its Biologics License Application for Deramiocel, indicating the need for additional clinical data to demonstrate effectiveness.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Capricor Therapeutics Inc (CAPR) stock price today?

The current price of CAPR is 25.4 USD — it has decreased -15.22 % in the last trading day.

arrow icon

What is Capricor Therapeutics Inc (CAPR)'s business?

Capricor Therapeutics, Inc. is a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment and prevention of rare diseases. The Company's program is focused on the development and commercialization of a cell therapy technology comprised of cardiosphere-derived cells (CDCs) for the treatment of Duchenne muscular dystrophy (DMD). Its lead product candidate deramiocel (also referred to as CAP-1002), is an allogeneic cardiac-derived cell therapy. CAP-1002 is advancing through Phase III clinical development for the treatment of Duchenne muscular dystrophy (DMD). CAP-1002 demonstrates immunomodulatory, antifibrotic, and regenerative actions specifically tailored for dystrophinopathies and heart disease. It leverages its exosome technology, using its StealthX platform in preclinical development focused on the areas of vaccinology, targeted delivery of oligonucleotides, proteins, and small molecule therapeutics.

arrow icon

What is the price predicton of CAPR Stock?

Wall Street analysts forecast CAPR stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for CAPR is 21.25 USD with a low forecast of 13.00 USD and a high forecast of 29.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Capricor Therapeutics Inc (CAPR)'s revenue for the last quarter?

Capricor Therapeutics Inc revenue for the last quarter amounts to 0.00 USD, decreased -100.00 % YoY.

arrow icon

What is Capricor Therapeutics Inc (CAPR)'s earnings per share (EPS) for the last quarter?

Capricor Therapeutics Inc. EPS for the last quarter amounts to -0.54 USD, increased 42.11 % YoY.

arrow icon

What changes have occurred in the market's expectations for Capricor Therapeutics Inc (CAPR)'s fundamentals?

The market is revising Downward the revenue expectations for Capricor Therapeutics, Inc. (CAPR) for FY2025, with the revenue forecasts being adjusted by -49.58% over the past three months. During the same period, the stock price has changed by 276.85%.
arrow icon

How many employees does Capricor Therapeutics Inc (CAPR). have?

Capricor Therapeutics Inc (CAPR) has 160 emplpoyees as of December 05 2025.

arrow icon

What is Capricor Therapeutics Inc (CAPR) market cap?

Today CAPR has the market capitalization of 1.16B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free